Arcutis Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. The company concentrates on immune mediated conditions such as psoriasis, atopic dermatitis, and seborrheic dermatitis. Its lead product, ZORYVE cream 0.3%, is a once daily topical formulation of roflumilast, a potent and selective phosphodiesterase 4 inhibitor. Arcutis also markets ZORYVE foam 0.3% for seborrheic dermatitis and scalp and body psoriasis, and ZORYVE cream 0.15% and 0.05% for atopic dermatitis across multiple age groups. Beyond its commercial portfolio, the company advances a pipeline that includes ARQ-234, a fusion protein targeting the CD200 receptor for potential use in atopic dermatitis and other inflammatory conditions. Arcutis leverages a deep expertise in dermatology and inflammation to create steroid free therapies designed for chronic use on all body areas.

The company generates revenue primarily from sales of its ZORYVE products in the United States and Canada, including creams and foams approved for psoriasis, atopic dermatitis, and seborrheic dermatitis. Additional revenue stems from licensing and collaboration agreements that provide up front payments, milestone payments, and royalties on net sales of licensed products in territories such as Greater China, Southeast Asia, and Japan. Arcutis also earned promotion fees under its former agreement with Kowa Pharmaceuticals America, Inc., which was terminated in January 2026. The firm’s collaborations with Huadong and Sato include potential sales milestone payments and royalty streams, while the AstraZeneca license provides quarterly royalty payments on worldwide net sales of roflumilast based topical products. Although the company relies on third party manufacturers for drug substance and product, its commercialization efforts in North America drive the core of its top line growth.

Arcutis Biotherapeutics occupies a niche in the dermatology market by offering steroid free topical therapies that inhibit phosphodiesterase 4, a mechanism distinct from corticosteroids, calcineurin inhibitors, and JAK inhibitors. The company’s ZORYVE line competes with established treatments such as topical steroids, Eucrisa, Opzelura, VTAMA, and biologic agents like Dupixent and Skyrizi. Arcutis differentiates its products through favorable tolerability, once daily dosing, and applicability to sensitive areas such as the face and intertriginous regions. A strong intellectual property portfolio, including issued patents that protect its cream formulation through 2037 and its foam formulation through 2042, provides exclusivity and shields the core products from generic competition. The firm also benefits from a growing patient base estimated at millions of individuals in the United States suffering from plaque psoriasis, atopic dermatitis, and seborrheic dermatitis, which supports its commercial expansion efforts.

The company serves dermatologists, primary care practitioners, pediatricians, and patients who require treatment for plaque psoriasis, atopic dermatitis, or seborrheic dermatitis in the United States and Canada. Its products are prescribed across various practice settings, including academic medical centers, community clinics, and private offices. While specific customer names are not disclosed, the firm’s commercial strategy targets health care providers that manage large volumes of inflammatory skin disease and patients seeking chronic, steroid free therapeutic options.